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Abstract
The Vibrio cholerae lipopolysaccharide O1 antigen is a major target of bacteriophages and the human immune system and is
of critical importance for vaccine design. We used an O1-specific lytic bacteriophage as a tool to probe the capacity of V.
cholerae to alter its O1 antigen and identified a novel mechanism by which this organism can modulate O antigen
expression and exhibit intra-strain heterogeneity. We identified two phase variable genes required for O1 antigen
biosynthesis, manA and wbeL. manA resides outside of the previously recognized O1 antigen biosynthetic locus, and
encodes for a phosphomannose isomerase critical for the initial step in O1 antigen biosynthesis. We determined that manA
and wbeL phase variants are attenuated for virulence, providing functional evidence to further support the critical role of
the O1 antigen for infectivity. We provide the first report of phase variation modulating O1 antigen expression in V. cholerae,
and show that the maintenance of these phase variable loci is an important means by which this facultative pathogen can
generate the diverse subpopulations of cells needed for infecting the host intestinal tract and for escaping predation by an
O1-specific phage.
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Introduction
Lipopolysaccharide (LPS) is a prominent constituent of the
outer membrane of Gram-negative bacteria. The LPS molecule is
divided into three components; lipid A, core oligosaccharide and
O-specific polysaccharide (or O antigen). The structure of the O
antigen typically defines the serogroup of an organism, and over
200 serogroups of Vibrio cholerae are currently recognized [1].
Interestingly, the O1 serogroup has been and continues to be the
dominant cause of both endemic and epidemic cholera throughout
the world, though the reasons for this are unknown. The incidence
of cholera worldwide is steadily increasing, and the cumulative
number of reported cases in 2010 was nearly double what it was in
2009 [2]. When considering the level of gross under-reporting, the
actual global disease burden is estimated to be 3–5 million cases
and more than 100,000 deaths [3,4]. The observed increase in
reported cases in 2010 is largely due to a recent outbreak of an O1
strain that started in Haiti: Even more concerning is the
observation that 53% of the global total of the number of
reported deaths from cholera in 2010 occurred in Haiti in a period
of only 70 days [2]. These observations highlight the fragile nature
of impoverished and tragedy-struck nations to the rapid onset of
cholera epidemics.
The V. cholerae O1 antigen is composed of 12–18 repeating units
of a(1,2)-linked D-perosamine (4-amino-4,6-dideoxy D-mannose)
residues, the amino groups of which are acylated with tetronate (3-
deoxy-L-glycero-tetronic acid) (Fig. S1) [1,5–8]. The genes
currently described as being required for the synthesis of the O1
antigen are located on chromosome 1 of the V. cholerae O1 N16961
genome between open reading frames (ORFs) VC0240 (gmhD) and
VC0264 (rjg) (Fig. 1A) [9]. This region (the wbe or rfb region) was
originally identified through the heterologous expression of the V.
cholerae O1 antigen in Escherichia coli K-12 [10]. Additional genes
required for the synthesis of the O1 antigen in V. cholerae were
subsequently identified [11], however all O1 antigen biosynthetic
genes studied to date have been between the gmhD and rjg flanking
genes. The genes responsible for O1 antigen biosynthesis have
been placed into the following five groups according to putative
function: perosamine biosynthesis (VC0241–VC0244) [12]; O
antigen transport (VC0246–VC0247) [13]; tetronate biosynthesis
(VC0248–VC0252) [14]; O antigen modification (VC0258)
[15,16]; and additional genes essential for O antigen biosynthesis
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for the biosynthesis of perosamine has been proposed by Stroeher
et al. [12] (Fig. 1B). In this pathway, which is based solely on
homology comparisons, the first step is the conversion of fructose-
6-phosphate (F6P) to mannose-6-phosphate (M6P) by ManC (a
predicted type II phosphomannose isomerase [PMI]). M6P is then
converted to mannose-1-phosphate (M1P) by ManB, and then to
GDP-mannose by ManC. GDP-mannose is converted to GDP-4-
keto-6 deoxymannose by WbeD and then GDP-perosamine by
WbeE. PMIs (E.C. 5.3.1.8) catalyze the reversible isomerization of
M6P to F6P and are divided into three families on the basis of
amino acid sequence [17]. Type I PMIs are monofunctional
enzymes and include proteins from humans to bacteria including
E. coli [18] and Salmonella enterica serovar Typhimurium [19]. Type
II enzymes are bacterial bifunctional enzymes possessing both
PMI and guanosine diphospho-D-mannose pyrophosphorylase
(GMP) activity (for the conversion of M1P into GDP-mannose)
in distinct catalytic domains [20]. PMIs play critical roles in
mannose catabolism and in the supply of GDP-mannose, which is
necessary for the mannosylation of various structures including
LPS.
The distal location of the O antigen extending outward from the
bacterial surface positions it at the interface between the bacterium
and its environment. As such, the O antigen is important for
protection from various environmental stresses including antibiot-
ics and the host immune response [21,22]. The O antigen is also
consequently the target of both the immune system and
bacteriophages, which can independently apply powerful selective
forces. As such, cell surface structures, including the O antigen, are
frequently observed to exhibit high levels of variation [23].
Examples of phase variable surface structures are abundant in
bacterial pathogens and include Haemophilus influenzae lipooligo-
saccharide (LOS) [24–26], Neiserria meningitidis LOS [27], Helico-
bacter pylori LPS [28,29] and Campylobacter jejuni LOS [30,31]. The
loci responsible for phase variable expression of these structures,
often referred to as contingency loci, are thought to offer a
preemptive strategy to increase diversity necessary for bacterial
adaptation in unpredictable environments [32]. Phase variation
can be mediated by DNA polymerase slipped-strand mispairing
across simple sequence repeats, and when located in coding
sequences, can lead to a frameshift mutation resulting in the
production of truncated, often nonfunctional, peptide. Homopol-
ymeric nucleotide tracts are one subset of simple sequence repeats
commonly observed to undergo frequent expansion and contrac-
tion resulting in reversible heritable phenotypic variation [23,32].
One variation of the V. cholerae O1 antigen that has been
demonstrated and which defines the two serotypes, Ogawa and
Inaba, is the presence or absence, respectively, of a terminal
methyl group [16]. The two serotypes can undergo serotype
conversion during epidemics or in endemic areas [33–38].
Spontaneous mutations in the predicted methylase wbeT
(VC0258) are linked to this switching phenotype [15] and may
be involved in immune evasion as cross-serotype protection is
limited. In contrast to the immune pressure being somewhat
specific for a given serotype, bacteriophages that target the O1
antigen for use as a receptor may not be serotype-specific. In this
regard, it has recently been reported that the absorption of several
different O1-specific phages to V. cholerae can be modulated by its
cyclic AMP (cAMP)-cAMP receptor protein regulatory system,
suggesting that regulatory pathways may exist that alter O1
antigen abundance or surface organization [39]. We recently
described ICP1, an O1-specific, but serotype nonspecific V. cholerae
phage that is prevalent in cholera patient stool samples in the
cholera endemic region of Bangladesh [40]. ICP1 is likely related
to the previously described phage JSF4 [41]. We sought to
investigate the mechanisms employed by pathogenic V. cholerae O1
to resist ICP1 infection and discovered two phase variation
mechanisms by which V. cholerae O1 displays intra-strain O antigen
heterogeneity. This heterogeneity is mediated by two contingency
loci involved in tetronate biosynthesis (wbeL) and a previously
unrecognized PMI (manA) critical for perosamine biosynthesis.
Results/Discussion
Identification of contingency loci controlling V. cholerae
O1 antigen biosynthesis
Plaques resulting from the infection of a wild type V. cholerae O1
strain with the O1-specific phage ICP1 were routinely observed to
have colonies growing in the center indicating the presence of
phage resistant isolates. Four independent phage resistant isolates
were subjected to whole genome resequencing and the majority of
the isolates (three of four) had single nucleotide deletions that
mapped to homonucleotide (poly-A) tracts within two genes. Two
mutants were found to have a deletion in the poly-A (A8) tract
starting at nucleotide position 108 in wbeL, a gene that is predicted
to be required for tetronate synthesis [14]. The full-length WbeL
protein is 471 amino acids and a single nucleotide deletion within
the poly-A tract results in the production of a truncated peptide of
42 amino acids due to a premature stop codon 12 nucleotides
downstream of the poly-A tract (Fig. S2). wbeL is unique to V.
cholerae O1 strains, and the poly-A tract is 100% conserved in all 37
V. cholerae O1 strains available for analysis through the National
Center for Biotechnology Information (NCBI) DNA sequence
database.
Purified LPS from a wbeL* (A7) phase variant shows a distinct
lower molecular weight pattern on a silver stained SDS-PAGE gel
(Fig. 2), although the strain exhibits a normal slide agglutination
phenotype with anti-Ogawa typing serum (Table 1). The wbeL*
strain is completely resistant to infection with ICP1, and
accordingly purified LPS from this strain shows no inhibition of
ICP1 (Table 1). To test the possibility that the wbeL*A 7 frame shift
exerts a polar effect on downstream genes, which also contribute
Author Summary
The O1 serogroup of Vibrio cholerae is the most common
cause of the potentially fatal diarrheal disease cholera,
which remains a significant global health burden world-
wide. The O1 antigen is a constituent of the lipopolysac-
charide portion of the outer membrane, and its location on
the bacterial surface makes it a major target of both the
immune system and bacteriophages. We used an O1
-specific bacteriophage as a tool to understand if, and
how, V. cholerae can alter O1 antigen expression. We
discovered that two genes, which are critical for O1
antigen biosynthesis, are subject to phase variation.
Additionally, one of the phase variable genes we identified
was not previously known to play a role in O1 antigen
biosynthesis in V. cholerae. Phase variation is a well-
recognized mechanism many other bacterial pathogens
use to generate variable expression of surface compo-
nents, and this is generally thought to help these
organisms evade the immune system. Phase variation
has not previously been described as a widespread
mechanism used by V. cholerae, furthermore, this is the
first report that V. cholerae O1 is capable of generating
diverse populations with variable and unique O1 antigen
expression.
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analysis and found that wild type LPS production and ICP1
sensitivity are restored when the wbeL* mutant is complemented
with wbeL in trans (Fig. 2). This indicates that the observed
phenotypes are a consequence of the loss of WbeL expression and
not due to polar effects of the wbeL* mutation. To further confirm
this, an in-frame deletion in wbeL was constructed and comple-
mentation analyses were performed. The DwbeL strain is devoid of
O1 antigen (Fig. 2) and accordingly exhibited no agglutination
with anti-Ogawa typing serum (Table 1), and these phenotypes
can be complemented with wbeL in trans (data not shown). Since
the phenotype of the in-frame deletion mutant is not consistent
with the original wbeL* mutation, we hypothesized that the wbeL*
allele maintains some O1 antigen biosynthetic function in the cell.
Consistent with this, when the DwbeL strain is complemented with
the wbeL* allele in trans, agglutination in the presence of anti-
Ogawa typing serum is restored while the strain maintains
complete resistance to ICP1, just like the original wbeL* strain
(Table 1). The DwbeL mutant expressing wbeL* in trans also
produces a small amount of lower molecular weight LPS like the
original wbeL* strain (data not shown). To further address the
biosynthetic function of the wbeL* allele, we explored two possible
explanations for the phenotype of the wbeL* phase variant. First,
that the presence of the truncated 42 amino acid peptide produced
by the wbeL* allele is necessary and sufficient to allow V. cholerae O1
to elaborate the lower molecular weight LPS observed (Fig. 2). To
test this hypothesis we constructed a deletion in the remainder of
the coding sequence downstream of the premature stop codon in
wbeL*. Purified LPS from a wbeL* strain expressing only the 42
amino acid peptide lacks O1 antigen substituted LPS (Fig. 2),
which rules out this hypothesis. The second hypothesis that we
tested to account for the biosynthetic role of the wbeL* allele is that
it allows some functional WbeL protein to be made because the
wbeL* allele is subject to nonstandard decoding (ribosomal frame
shifting or transcriptional slippage at the A7 tract). This in turn
would allow for a small amount of tetronate modification to occur,
resulting in a lower molecular weight but still compositionally (and
antigenically) normal O antigen (which is consistent with the
observation that the wbeL* phase variant agglutinates in the
presence of anti-Ogawa typing serum (Table 1). To test this
hypothesis, we made silent point mutations within the A7 tract in
wbeL* (A7 to TAAGAAA) designed to prevent non-standard decoding
as well as prevent further slipped-strand mispairing during
replication and characterized the ability of this strain (referred to
as wbeL* PL for phase-locked) to produce O1 antigen substituted
LPS. The point mutations in wbeL* PL abolished the ability of this
strain to make O antigen substituted LPS, which supports the
conclusion that the wbeL* allele maintains biosynthetic function by
allowing some functional WbeL protein to be produced through
nonstandard decoding, and that this is dependent on the A7 tract.
The mechanism responsible is not currently known, nor is it
known if there are other sequence motifs within the wbeL* allele
that facilitate the +1 frameshifting needed to restore the reading
frame. It is important to emphasize that the observed lower
molecular weight pattern of purified LPS from wbeL* is not due to
reversion of A7 to A8 in the genome of a substantial subset of the
population, because if that were the case we would observe a small
amount of wild type length O1 antigen and not the unique species
observed for the wbeL* strain. These results further suggest that
tetronate acylation of the perosamine backbone is necessary for
incorporation of the O1 antigen into the LPS molecule, and this
may be required for recognition and subsequent transport of the
Figure 1. Genetic organization of the O1 antigen biosynthetic locus and the proposed pathway for the synthesis of perosamine in
V. cholerae O1. A) Pictorial representation of the genes in the O1 antigen biosynthetic (wbe) locus. The annotated ORFs and their orientation are
indicated by block arrows (drawn to scale). The genes currently described as being required for O1 antigen biosynthesis are located between the
gmhD and rjg flanking genes. Work presented here however extends the O1 antigen biosynthetic cluster to include VC0269 (manA). The locus can be
divided up into five major groups according to putative function that are indicated by the same color arrow. B) Proposed biosynthetic pathway for
perosamine in V. cholerae O1. The pathway includes ManA for the conversion of F6P to M6P and eliminates ManC (indicated in grey) as the enzyme
responsible for the initial step of perosamine biosynthesis.
doi:10.1371/journal.ppat.1002917.g001
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ABC transporter and/or for efficient ligation of the O antigen
polymer to the lipid A-core by WaaL ligase [42]. Importantly,
these data demonstrate that the lower molecular weight O1
antigen produced by the wbeL* mutant somehow endows V. cholerae
with full resistance to ICP1.
The second mutation identified in ICP1-resistant colonies from
the center of plaques also mapped to a poly-A tract, and this
localized to VC0269, which we designate manA for reasons
explained below. manA has two poly-A (A9) tracts and, as illustrated
in Fig. 1A, is located approximately 4 kbp downstream of the right
junction gene (rjg=VC0264), which was thought to delineate the
end of the O1 antigen biosynthetic locus in V. cholerae. ManA
shows homology to type I PMIs that catalyze the reversible
isomerization of F6P to M6P, which is the first step in perosamine
biosynthesis (Fig. 1B). Like wbeL, manA is also specific to V. cholerae
O1 strains: All 37 V. cholerae O1 strains available for bioinformatic
analysis have manA and it is highly conserved between these strains
with the exception of two strains which have the manA*( A 8) allele
resulting from a single nucleotide deletion in the first poly-A tract
(these latter strains are designated 2740–80 and HC-61A1). The
full length ManA protein is 399 amino acids, and a single
nucleotide deletion within the first poly-A tract is predicted to
result in a truncated peptide 81 amino acids long, while a single
nucleotide deletion within the downstream poly-A tract (designat-
ed manA*) produces a truncated peptide 207 amino acids long (Fig.
S3). LPS purified from manA* after overnight growth looks
identical to the parental strain (Fig. 2). However, purified LPS
from the manA* strain does not bind and inhibit ICP1 as efficiently
as a equal amount of LPS purified from the parental strain
(Table 1), which is consistent with this mutant being partially
phage resistant (Fig. 2 and Table 1). These results leave open the
possibility that while manA* produces wild type length O1 antigen,
the overall abundance of O1 antigen substituted LPS is less than
wild type, and this translates into fewer available receptors for
ICP1. Phage infection is a complex process, which can require
sequential receptor binding steps. For example T4 infection is
initiated by the reversible attachment of at least three of the six
long tail fibers to the outer core of the LPS, but does not result in
DNA injection unless the six short tail fibers successfully engage
their receptors on the inner core of the LPS [43–45]. Throughout
the course of this study isolates were obtained with a frameshift in
either poly-A tract in manA and these isolates were phenotypically
indistinguishable from one another with regard to phage sensitivity
and agglutination with anti-Ogawa typing serum (data not shown).
Similarly, a strain harboring an in-frame deletion of manA was
phenotypically indistinguishable from the manA phase variants
(Fig. 2 and Table 1), indicating that both frame-shift mutations
function as manA nulls.
manA and manA-2, but not manC, are important for
perosamine biosynthesis
manA does not appear to be required for producing full length O
antigen as indicated by SDS-PAGE and silver staining of LPS
(Fig. 2), and yet the manA* strain is partially resistant to ICP1,
which specifically requires the O1 antigen for infection. These
observations led us to speculate that there is likely another gene
that can contribute to the conversion of the F6P to M6P in V.
cholerae O1. We noted the presence of another annotated type I
PMI in the V. cholerae O1 genome, VC1827, hereafter designated
manA-2. manA-2 is located immediately downstream of a mannose
permease encoded by VC1826 [46], but is not linked to the O1
antigen biosynthetic cluster. manA and manA-2 are 65% identical at
the nucleotide level over 70% of their sequence, and at the protein
level, they are 59% identical over 97% of their sequence. manA-2
has a higher GC content than manA (46.1% compared to 42.1%,
respectively) and its GC content is much closer to the overall GC
content of the entire V. cholerae N16961 genome (,47% [47])
suggesting manA may have been recently horizontally acquired.
Unlike manA, manA-2 is found in non-O1 V. cholerae. In other
Gram-negatives, including E. coli and S. Typhimurium, the manA
gene generally maps as an independent gene not associated with
the LPS gene cluster due to its role in mannose metabolism
[48,49], although in these organisms the PMI activity of the
unlinked manA is required for O antigen synthesis [50,51]. In
organisms that do not metabolize mannose, the manA gene is
generally absent [49]. Some bacteria have a bifunctional type II
PMI-GMP (typically referred to as ManC) encoded in the LPS
biosynthetic cluster. Monofunctional and bifunctional forms of
ManC are not clearly distinguishable on the basis of size or even
sequence similarity [49]. Indeed ManC (VC0241) in V. cholerae O1
has the bioinformatic designation of a type II PMI, however our
results below suggest this enzyme lacks PMI activity.
The presence of two putative type I PMIs in V. cholerae O1 led us
to investigate the phenotypes of single and double mutants with
regards to O antigen biosynthesis. A mutant lacking manA-2 was
indistinguishable from wild type with regard to phage sensitivity
and LPS pattern on a gel (Fig. 2 and Table 1), indicating that
manA-2 is not important for O antigen biosynthesis under the
conditions tested. However, in the absence of manA, manA-2
becomes important since the manA* DmanA-2 double mutant is
completely phage resistant and produces very little fully length
LPS (Fig. 2). Another potential source of M6P for perosamine
biosynthesis is through the conversion of exogenously acquired
mannose to M6P by a hexokinase, which led us to determine if
trace mannose present in the growth media (Luria-Bertani [LB]
broth) contributed to the small amount of O1 antigen still visible in
the manA* DmanA-2 double mutant. Indeed, this small amount of
O1 antigen substituted LPS is absent when the double mutant is
grown in M9-glucose, but is present when the double mutant is
grown in M9-glucose plus mannose (Fig. 2), demonstrating that
exogenous mannose is responsible for the small amount of O1
antigen substituted LPS in the double mutant. Similar results have
been observed in E. coli and S. Typhimurium manA mutants, which
are unable to synthesize O antigen without the inclusion of
mannose in the growth media [50,51]. Also consistent with these
results, we observed that our double manA* DmanA-2 mutant is
unable to grow in M9-mannose owing to the critical nature of type
I PMIs in the conversion of M6P to F6P as a substrate for
glycolysis. These results indicate that manC in V. cholerae O1, which
was hypothesized to catalyze the first reaction in biosynthesis of
perosamine (Fig. 1B) [12], is not active as a bifunctional PMI-
GMP, and is likely only important for the later steps in perosamine
biosynthesis for converting M1P to GDP-mannose. As type II
PMIs possess two catalytically distinct domains for each PMI and
GMP activity [20], attempts were made to construct mutant manC
alleles that should be defective for PMI activity alone (data not
shown) but all constructs resulted in complete depletion of the O1
antigen, suggesting that these mutations had an inadvertent
negative impact on the GMP activity of the protein. The reason
behind V. cholerae O1 possessing two type I PMIs is thus not clear,
although it suggests that they each have their primary roles: manA
in O antigen biosynthesis and manA-2 in mannose metabolism,
though it is unclear what factors define those functional roles. A
search for other bacteria harboring multiple annotated type I
PMIs reveals a limited number of organisms including strains of
Vibrio vulnificus (Accession No. NC_005140), Vibrio parahaemolyticus
(NC_004605), and Yersinia enterocolitica (NC_015224); however, to
V. cholerae O1 Antigen Phase Variation
PLOS Pathogens | www.plospathogens.org 4 September 2012 | Volume 8 | Issue 9 | e1002917Figure 2. LPS profiles of wbeL* and manA* phase variants and related strains by SDS-PAGE and silver staining. Strains for LPS
purification were grown overnight in LB (or M9-glucose +/2 mannose as indicated) at 37uC with shaking. The bacterial strains are indicated above the
lanes and the positions of the fully substituted LPS with attached O antigen and lipid A core oligosaccharide (OS) precursor are indicated.
Approximately 5 mg of purified LPS was loaded into each lane, with the exception of the lanes containing LPS prepared from M9 cultures in which
,30 mg of LPS was loaded. A strain lacking O1 antigen transferase activity, waaL, which has no O1 antigen, was used as a control for assessing the
electrophoretic migration of the lipid A-core oligosaccharide. The ability of ICP1 to infect these strains as evidenced by plaque formation with
bacteria grown to OD600,0.5 is indicated as follows: (++) clear plaques, (+) turbid plaques, (2) no plaques.
doi:10.1371/journal.ppat.1002917.g002
Table 1. Summary of phenotypes of single and double mutants of V. cholerae O1 and their reverted or trans-complemented
derivatives as analyzed by silver stained SDS-PAGE, phage sensitivity, and agglutination by anti-Ogawa typing serum.
Strain
O antigen
substituted LPS
a
ICP1
sensitivity
b
Log10 inhibition
of purified LPS
c
Agglutination
with serum
WT ++ ++ 2.3 +
waaL None 2 n.d. 2
wbeL* + 2 0 +
wbeL*p wbeL ++ ++ n.d. +
DwbeL None 2 0 2
DwbeL pwbeL ++ ++ n.d. +
DwbeL pwbeL* + 2 n.d. +
wbeL* (42 AA) None 2 n.d. 2
wbeL* PL None 2 n.d. 2
wbeL* rev ++ ++ n.d. +
manA* ++ + 1.6 +
DmanA ++ + 1.6 +
DmanA-2 ++ ++ n.d. +
manA* DmanA-2 + 2 0 +
DmanA DmanA-2 (in M9+glucose) None 2 0 2
DmanA DmanA-2 (in M9+glucose+mannose) + 2 n.d. +
manA rev ++ ++ n.d. ++
aThe pattern of purified LPS from strains grown overnight in LB (unless otherwise indicated) was visualized by SDS-PAGE and silver staining and the phenotype of each
strain was categorized as follows: (++) wild type appearance of O antigen substituted LPS, (+) altered levels or appearance of O antigen substituted LPS, (None) no O
antigen substituted LPS was observed.
bThe ability of ICP1 to infect these strains as evidenced by plaque formation with bacteria grown to OD600,0.5 is indicated as follows: (++) clear plaques, (+) turbid
plaques, (2) no plaques.
cThe ability of purified LPS to inhibit plaque formation by ICP1 was determined using 10 mg of purified LPS and is indicated as the average log10 inhibition of two
independent assays. n.d. not done.
doi:10.1371/journal.ppat.1002917.t001
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these other organisms are not known.
As mentioned previously, the O1 antigen biosynthetic cluster
was originally identified through the heterologous expression of
the V. cholerae O1 antigen in E. coli [10], and all O1 antigen
biosynthetic genes studied thus far have been between the gmhD
and rjg flanking genes. manA was likely not identified as part of this
biosynthetic pathway because its function was complemented by
the E. coli manA gene, permitting expression of the O1 antigen in
this host. Additional genes required for O1 antigen biosynthesis
were subsequently identified following the initial report by
Manning et al. [11], and were similarly likely missed because the
phenotype was masked in E. coli. Blokesch and Schoolnik [52]
provided some additional support that further extends the O1 wbe
region downstream of rjg. They observed that when serogroup
conversion of V. cholerae O1 to O139 occurred through uptake of
O139 donor DNA during natural transformation, the crossovers
were often localized within or downstream of VC0271 at the right
junction, and the location of the left junction was within or
upstream of gmhD. These results coupled with our observation that
manA participates in O1 antigen biosynthesis suggests that the wbe
region extends approximately 8 kbp downstream of rjg (Fig. 1B).
There are six genes currently annotated in addition to manA in this
region (Fig. 1A), however it remains to be seen if these other genes
do in fact participate in O1 antigen biosynthesis.
V. cholerae O1 wbeL and manA phase variants are
defective for colonization of the small intestine
The ability of wbeL* and manA* phase variants to colonize the
small intestine was assessed in competition assays in the infant
mouse model. The wbeL* strain is attenuated over 1000-fold
(Fig. 3). We did not anticipate such a high level of attenuation
given that this strain still elaborates LPS (although it is a lower
molecular weight form, Fig. 2). Interestingly, the altered LPS
produced by the wbeL* strain does provide some advantage over
not having any O1 antigen, as is apparent by the significantly
lower competitive index (CI) for the DwbeL strain (p,0.05, Mann-
Whitney U test). To rule out secondary mutations, we chose to use
revertant strains in vivo to avoid potential complications concerning
plasmid loss and non-wild type gene expression levels during
infection. The colonization defect observed for the wbeL* strain is
absent when the poly-A (A7) tract is reverted to wild type length
(A8) (Fig. 3), demonstrating that the virulence defect is due to the
wbeL* allele. The manA* phase variant, which produces an
apparently full length LPS but which is partially resistant to
ICP1, is over ten-fold attenuated for colonization, and this defect is
absent when the A8 tract is reverted to wild type length (A9) (Fig. 3).
We anticipated that a manA* DmanA-2 double mutant would be
significantly more attenuated owing to a major reduction in O1
antigen produced by the strain (Fig. 2). However, although we did
observe a further decrease in the CI for manA* DmanA-2 compared
to manA*, it was not significant (p=0.42) (Fig. 3). To try and
explain this, we hypothesized that the selective pressure exerted on
the manA* DmanA-2 double mutant in the small intestine is
sufficient to select for spontaneous revertants which would
potentiate the observed moderate drop in CI. To test this, we
patched manA* DmanA-2 isolates recovered from mouse intestines
onto M9-mannose agar plates. Consistent with our hypothesis,
roughly half of isolates recovered from mice after 24 h of infection
had regained the ability to grow on mannose, and subsequent
sequencing revealed that these strains had reverted to the wild
type, in-frame poly-A tract in manA. Conversely, we were unable to
detect spontaneous revertants of the wbeL* or manA* strains among
the isolates recovered from mouse intestines infected with those
strains, suggesting that the A7 wbeL* allele is less prone to reversion
by slipped-strand mispairing, and that the A8 allele in manA* is not
under enough selective pressure to revert as long as ManA-2 is
functional. Our inability to detect wbeL* revertants is likely due to
the experimental limitation that there are so few wbeL* isolates
recovered from infected mice that we were only able to test
,100 CFU.
The manA revertants recovered from intestines of mice infected
with the manA* DmanA-2 strain were effectively equivalent to
DmanA-2, which we previously observed has no effect on LPS
biosynthesis or virulence (Fig. 2 and Fig. 3). Confirming this, we
also competed the double mutant with in-frame deletions in both
manA and manA-2 and observed the anticipated significant increase
in attenuation (.2000-fold) compared to a manA* phase variant
alone (p,0.05 Mann-Whitney U test) (Fig. 3). Furthermore, the
double DmanA DmanA-2 mutant is significantly more attenuated
when grown in M9-glucose prior to infection than when it is
grown in LB which contains trace mannose (p,0.05 Mann-
Whitney U test). Consistent with this, a comparable CI was
observed for the two strains that are devoid of all O1 antigen prior
to infection (DmanA DmanA-2 grown without exogenous mannose,
and DwbeL) (Fig. 3). In vitro control competitions revealed that the
observed defects were specific to the in vivo environment, with the
exception of the DwbeL mutant, which has a ,10-fold defect in vitro
compared to the wild type (data not shown). The nature of this
defect is not known, but it could be due to the build-up of O
antigen and/or LPS intermediate products in this strain which,
unlike the wbeL* phase variant, is unable to elaborate any O1
antigen on the surface. Consistent with this, mutants harboring
transposon insertions in wbeL, which also showed a decreased
colonization phenotype in infant mice, also exhibited a decreased
CI in in vitro control competitions [53].
V. cholerae O1 phase variants are sensitive to the
antimicrobial peptide polymyxin B
Human intestinal epithelial cells produce antimicrobial peptides
that are critical components of the host innate defense mechanism
[54]. Antimicrobial peptides are inherently structured to target the
membrane of bacteria because they are highly basic and have a
substantial portion of hydrophobic residues [55,56]. The net
positive charge of these peptides facilitates their electrostatic
interaction with negatively charged phospholipid groups or the
lipid A anchor of LPS on the Gram-positive or Gram-negative
bacterial membranes, respectively, allowing them to induce lysis
and bacterial cell death. In order for an antimicrobial peptide to
gain access to the Gram-negative outer membrane it must first
traverse the barrier presented by the sugar chains of the O antigen
layer. Perturbations to the LPS have been shown previously to
alter resistance of V. cholerae to antimicrobial peptides; specifically,
Matson et al. [57] and Hankins et al. [58] have investigated the
structural importance of lipid A with regards to peptide resistance,
and Nesper et al. [59] suggested that mutations affecting the LPS
core oligosaccharide have a more dramatic affect on antimicrobial
peptide resistance than mutations affecting O1 antigen biosynthe-
sis (although only a rough strain was tested in those experiments).
We investigated the susceptibility of wbeL* and manA* phase
variants and their trans-complemented derivatives to the antimi-
crobial peptide polymyxin B by determining their survival in
killing assays. We observed that the wbeL* mutant exhibited a very
low level of survival (Fig. 4A). This phenotype could be
complemented and survival levels could be restored to wild type
when this mutant was expressing wbeL in trans, again supporting
the previous data suggesting there is no polar effect of wbeL* on
genes downstream. With regards to the manA* phase variant, we
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manner. There was intermediate sensitivity of this strain to
polymyxin B when the inoculum used for the killing assay was
grown up to early exponential phase (OD600=0.15) (Fig. 4A). In
contrast, when manA* was grown up to mid-exponential phase
prior to treatment with the peptide, wild type levels of survival
were observed (Fig. 4A). The phenotype observed at early
exponential phase with the manA* phase variant could be fully
complemented by expressing manA in trans (Fig. 4A), again
indicating the observed phenotypes are due to the loss of ManA.
We had also observed that phage sensitivity of the manA* phase
variant was growth phase-dependent, and these results parallel the
observations in the antimicrobial peptide assay, that is at
OD600=0.15, manA* is completely resistant to ICP1 and at
OD600$0.2, turbid plaques result from ICP1 infection (data not
shown). To address this puzzling observation, we purified LPS
from manA* and wild type at early and mid-exponential growth
phase (OD600=0.15 and OD600=0.5, respectively). In contrast to
the seemingly wild type appearance of purified LPS from manA*
after overnight growth (Fig. 2) and at mid-exponential phase, the
LPS pattern of manA* isolated at early exponential growth phase
showed very little O1 antigen substituted LPS (Fig. 4B). Since
analysis of the double manA* DmanA-2 mutant indicated that manA-
2 is important for O1 antigen synthesis only in the absence of
manA, we interpret these results to suggest the compensatory
activity of ManA-2 is incomplete during early exponential phase
growth in LB broth. The reason for this is not known, but may
relate to differences in expression, activity or localization of
ManA-2. In any event, a complete functional redundancy between
ManA and ManA-2 would have been at odds with the observation
that all V. cholerae O1 strains have a phase variable manA gene:
Specifically, the evolution of a contingency locus would be futile if
the encoded protein exhibited complete functional redundancy
with a non-phase variable gene.
In general, the results of the polymyxin B killing assays (Fig. 4A)
parallel the observed in vivo colonization defects (Fig. 3). Strains
that produce less O1 antigen substituted LPS (such as wbeL* and
DmanA DmanA-2) are highly susceptible to polymyxin B and are
more severely attenuated in vivo than manA*, which accordingly is
less susceptible to polymyxin B. These data suggest that the phase
variants are defective for in vivo colonization because they are more
susceptible the antimicrobial peptides present in the intestinal
tract.
Phase variation of wbeL occurs as the dominant
mechanism of O1 antigen variation in the face of
predation by phage in a simulated natural environment
V. cholerae O1 persists in the environment as a member of the
aquatic ecosystem where it is thought to associate with and use the
chitinous exoskeletons of zooplankton as a nutrient source [60].
The levels of V. cholerae O1 phages in the environment, including
potentially ICP1, have been shown to inversely correlate with
disease burden suggesting that phage predation in the natural
environment may contribute to the collapse of a given cholera
epidemic [41]. We investigated the potential for phage resistance
to develop in a simulated natural environment comprised of chitin
and pond water. A thousand CFU from independent cultures of
wild type V. cholerae O1 were inoculated into pond water with
chitin, and ICP1 was added at an MOI of 0.01. After 24 hours at
30uC, we observed that in all 11 pond microcosms to which ICP1
was added, the phage titer increased at least one million-fold (data
not shown). Bacterial levels in the uninfected control had increased
10,000-fold, while the bacterial levels in the infected microcosms
varied substantially from below the detection limit to levels nearly
comparable to that observed in the uninfected control (Table 2).
All isolates recovered from environments to which phage was
added were resistant to ICP1 infection. Furthermore, the majority
of isolates (63 out of 80 isolates, 79%) from independent
Figure 3. V. cholerae O1 phase variants are attenuated in vivo. Competition indices (CI) were determined between the strains indicated and
the parental strain carrying a lacZ deletion in infant mice 24 hours post infection. Each symbol represents the CI for an individual mouse and
horizontal lines indicate the median CI for each strain.
doi:10.1371/journal.ppat.1002917.g003
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frameshift allele (Table 2). We only observed heterogeneity in the
resistance mechanism for isolates from one microcosm (Table 2,
number 10), suggesting that in most cases phage predation resulted
in the clonal expansion of a single resistant mutant. We did not
observe any mutations in the poly-A tracts of manA, likely owing to
the incomplete ICP1 resistance afforded to V. cholerae with those
alleles. Control experiments with manA* and wbeL* variants as
input strains in the absence of phage confirmed that neither
mutant exhibit a decreased ability to grow in the simulated pond
microcosm (data not shown). Isolates from all microcosms to
which phage were added were also replica plated onto LB agar
containing 350 mg/mL polymyxin B (a concentration that permits
growth of the wild type parent but not wbeL* or manA*), and all
isolates were unable to grow. This indicates that the mutations that
occurred less frequently and that did not map to wbeL also likely
affected LPS biosynthesis. These results show that in a simulated
natural environment phage predation can occur with consequent
selection for bacteria with altered O1 antigen, and that the
dominant mechanism by which mutational escape is achieved is
through mutations in the poly-A tract in wbeL.
We also investigated the diversity of phage resistant mutants
that appeared in the center of plaques on LB plates by similarly
sequencing the poly-A tracts in wbeL and manA in 83 phage
resistant isolates. In contrast to the experiment designed to mimic
the natural aquatic environment, during selection in LB soft agar
overlays in which diffusion of phage and bacteria are relatively
limited, the mode of phage resistance is much more varied
although a substantial portion can be attributed to phase variation
in wbeL and manA (,20%); we found that six out of 83 isolates were
wbeL* phase variants and 11 out of 83 were manA* phase variants
(six of the 11 had a deletion that mapped to the first poly-A tract,
and the other five to the second poly-A tract). The reason for this
difference in frequency of wbeL* and manA* occurrence compared
to the pond microcosm is not known. However, as was mentioned
previously (and will be addressed below) the manA* mutation was
observed in sequenced V. cholerae O1 isolates; therefore it is
apparent there are relevant circumstances in which manA* phase
variants are selected for.
O1 antigen heterogeneity exists between clinical isolates
of V. cholerae O1
We wanted to determine if O antigen heterogeneity exists in the
population of V. cholerae excreted along with ICP1 phage from
patients during natural infection. To do this we obtained three
ICP1-positive stool samples collected from three patients admitted
to the International Centre for Diarrhoeal Disease Research,
Bangladesh (ICDDR,B) during a cholera epidemic in 2001.
Several representative isolates from all three stool samples were
analyzed and were found to be V. cholerae O1 Inaba and were
sensitive to ICP1. We tested the ability of these stool isolates to
become phage resistant by collecting phage resistant mutants from
the centers of plaques resulting from ICP1 infection and readily
isolated manA* and wbeL* phase variants (data not shown), showing
that these clinical isolates can phase vary at these contingency loci.
Next we screened many thousands of colonies from each of these
archived stool samples for the presence of manA* and wbeL* phase
variants, which we hypothesized might have arisen as a result of
ICP1 phage pressure during the patient infection. Since we
showed above that manA* and wbeL* phase variants are attenuated
in the infant mouse model, we expected that their frequency in the
human stool samples would be low or perhaps even undetectable
due to decreased fitness during infection of the human small
intestine. As we had done previously, we took advantage of the
observation that both phase variants exhibit increased sensitivity to
polymyxin B compared to the parental strain. We determined that
both the wbeL* and manA* phase variants obtained in vitro from
these clinical isolate strain backgrounds failed to grow on LB agar
Figure 4. V. cholerae O1 phase variants are more sensitive to the antimicrobial peptide polymyxin B. A) Strains were grown to
OD600=0.15 (hatched columns) or OD600=0.5 (solid black columns) and exposed to 50 mg/ml polymyxin B for 2 hours. After treatment, serial
dilutions of each culture were plated for enumeration to determine the percent survival compared to a mock-treated control. Data represents the
means and standard deviations of two independent experiments performed in technical duplicate. B) manA* phase variant exhibits O1 antigen
production dependent on growth phase. Approximately 2 mg of purified LPS was loaded into each lane.
doi:10.1371/journal.ppat.1002917.g004
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while the parental strain maintained its ability to grow. We
screened approximately 5,000 colonies from each stool sample by
replica plating and did not observe any isolates with increased
polymyxin B sensitivity.
In the above analysis we were limited by the number of
available archived stool samples, since routine practice is to purify
a single colony from a stool sample and store that for further
examination. While such single colony isolate collections cannot be
used to answer the question of whether O antigen heterogeneity
exists within the population of V. cholerae excreted from a single
patient, it does allow us to determine if O antigen heterogeneity
exists between isolates recovered from different patients. We
evaluated phage sensitivity of approximately 50 isolates recovered
from cholera patients at the ICDDR,B between 2001 and 2005.
Three of these isolates displayed resistance to ICP1 and were
characterized further. One of the clinical isolates has a mutation in
the second poly-A tract in manA. The other two resistant isolates
did not have mutations that mapped to the poly-A tracts in either
manA or wbeL, and examination of purified LPS from these strains
showed that they produce very little full length O-antigen
substituted LPS (data not shown), however the nature of the
observed defects is not known.
From these results it appears that, despite the hypothesized ICP1
phage pressure during infection and despite pressure from the host
immune system to reduce or alter the O1 antigen (O1 antigen is the
dominant antigen [61,62]), the intra-patient and inter-patient O1
antigen variability is quite low. In agreement with this, previous
studies have detected LPS mutants in mice following coinfection of
phage and V. cholerae O1, but at very low frequencies. Zahid et al.,
[63] estimated that the frequency of such mutants was on the order
of 10
28, and in accordance with our results, failed to detect phage-
resistance heterogeneity among V. cholerae O1 directly from human
stools. Additionally, despite relatively high levels of O1-specific
phage in the stool samples, V. cholerae O1 isolated from the same
stool samples remain completely susceptible to phage lysis [63–65].
Previous studies of V. cholerae O antigen negative strains or
strains with altered LPS structures were also found to be defective
in colonization of infant mice [53,59,63,66–69]. These results
support the assertion that O1 antigen-deficient V. cholerae would
be selected against during human infection due to the high fitness
cost associated with mutational escape. When put into the context
of our findings, it is fitting that mutational escape is frequently
conferred through phase variability, as a key feature defining this
mode of variability is its reversible nature [23,32,70]. Inherently
each cell will retain its ability to switch between expression states
(the switching rates of phase variable genes are typically between
10
22 to 10
25 [32]), and therefore the phenotype of a clonal
population of bacteria capable of phase variation will vary as a
function of selection. Predation of V. cholerae O1 in the
environment by O1 antigen-dependent lytic phage may rapidly
select for the subpopulation with altered O1 antigen mediated by
manA* and wbeL* frame-shifted contingency loci, and even
though those subpopulations are less suited for life in the
intestinal tract, positive selection (for example when this mixed
population is ingested by a human) results in enrichment of the
subpopulation with full O1 antigen expression. We were able to
experimentally confirm the reversibility of frameshift mutations
occurring at the poly-A tract in manA, however, we were unable
to do so for wbeL likely due to experimental limitations (discussed
above). It is possible that the observed mutational escape
mediated by the poly-A tract in wbeL is a function of
hypermutation and not phase variation (if it is not reversible).
However, we have clearly demonstrated the utility of these loci in
mediating alterations in the expression of the key V. cholerae
antigen and phage receptor.
Concluding comments
Pathogenic V. cholerae O1 has evolved to live in very diverse
environments including fresh water, salt water and the human
small intestine. The O1 polysaccharide antigen is the dominant
cholera antigen and can induce protective immune responses in
Table 2. Phage predation in a pond microcosm leads to the selection of wbeL* phage resistant mutants.
Microcosm
a Phage added
b Total CFU 24 h p.i.
c %W T
d ICP1 resistant isolates
% wbeL* % manA* % Other
1 2 2610
7 100 0 0 0
2 + 4610
6 01 0 0 0 0
3 + 4610
5 01 0 0 0 0
4 + 1610
6 01 0 0 0 0
5 + 4610
3 0 0 0 100
6 + 4610
5 01 0 0 0 0
7 + 6610
5 01 0 0 0 0
8 + ,d.l. 22 2 2
9 + 1610
7 0 0 0 100
10 + 6610
5 0 87.5 0 12.5
11 + 6610
5 01 0 0 0 0
12 + 4610
5 01 0 0 0 0
aIndependent cultures of wild type V. cholerae O1 were used to inoculate 10
3 CFU per microcosm containing pond water and chitin as a sole nutrient source.
bICP1 was simultaneously added at an MOI=0.01 where indicated.
c,d.l. is below the limit of detection for this assay (1 CFU).
dEight isolates from each microcosm were tested for resistance to ICP1. If no alteration to sensitivity was observed, the isolates were categorized as WT. If resistance was
observed than the poly-A tracts in wbeL and manA were sequenced. If resistance was observed and a frameshift in neither wbeL nor manA was observed, than the
isolates were categorized as other.
doi:10.1371/journal.ppat.1002917.t002
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guiding cholera vaccine development. The extent to which V.
cholerae can vary expression of the O1 antigen is not currently
appreciated. We demonstrate for the first time that the O1 antigen
is subject to phase variation and show that this is mediated by
three homonucleotide tracts in two genes (wbeL and manA), which
are critical for O1 antigen biosynthesis. The ubiquitous presence
of these phase variable homonucleotide tracts in all V. cholerae O1
strains points to the significant role they play in modulating
expression of this surface exposed antigen. Moreover, by
identifying manA as critical for O1 antigen biosynthesis, we have
extended the genome boundaries previously believed to contain all
the necessary genes for O1 antigen biosynthesis in V. cholerae. Phase
variation mediated by homonucleotide tracts has not been
previously well-documented in V. cholerae. To our knowledge, the
only prior report of phase variation in V. cholerae was that by
Carroll et al., [74] in which expression of the membrane bound
virulence regulator, TcpH, was observed to be subject to phase
variation mediated by a poly-G (G9) tract. However, with the
growing list of currently available V. cholerae O1 genome sequences,
it is clear that this tract is not well-conserved (only three of the
available 37 sequenced strains have this tract [data not shown]),
and thus this likely does not represent a wide-spread mechanism
employed by V. cholerae O1 to alter virulence expression.
Examination of the currently available V. cholerae O1 genome
sequences may facilitate further exploration of phase variation in
this organism; it is interesting to note that there are only twelve
homonucleotide tracts of nine or greater nucleotides in length
located within coding regions in the V. cholerae O1 N16961
genome, and several of these are located within known virulence
factors (data not shown), however the significance this remains to
be examined.
The biological role of phase variation in mucosal pathogens is
frequently anticipated to facilitate immune evasion in the host
[75]. However, in the case of the facultative pathogen V. cholerae,
our data point to the primary role for O1 antigen phase variation
as a strategy for dealing with the strong opposing selective
pressures of phage predation in the environment and the strict
requirement of O1 antigen for colonization of the intestinal tract.
Phase variation of these genes thus allows for a subset of the
population of V. cholerae being disseminated from a patient or being
ingested in contaminated water, to be resistant to O1-dependent
phages or to be virulent, respectively, thus contributing to the
overall fitness of this pathogen. We hypothesize that the host
immune response represents yet a second strong selective pressure
against the O1 antigen, though the effects of this on circulating
strains of V. cholerae within immune populations has not been
studied.
The ubiquitous presence and overall success of ICP1-related
phages is likely, at least in part, due to their use of a critical
virulence factor as a receptor [40]. Our observation that
mutational escape facilitated by wbeL and manA predominates ex
vivo strongly suggests that ICP1 is particularly adept at predation of
V. cholerae O1 within the human host where the requirement for
colonization and virulence necessitates the maintenance of the O1
antigen. This may suggest a mechanism whereby this phage and
the human host act synergistically to limit V. cholerae during
infection, and perhaps how phage contribute to the overall decline
of a given cholera epidemic as has been hypothesized [41,64]. It
remains to be seen if there are additional mechanisms employed
by V. cholerae O1 to evade phage predation, specifically within the
human intestinal tract, and how this arms race between ICP1 and
its bacterial host shapes the evolution of the circulating V. cholerae
O1 strains within the endemic region of Bangladesh.
Materials and Methods
Growth conditions
Strains were grown on Luria-Bertani (LB) agar or in LB broth at
37uC with 100 mg/ml streptomycin (Sm). When indicated M9
minimal media (supplemented with trace metals, vitamins (Gibco
MEM Vitamins, Invitrogen), 0.1% casamino acids) with 0.4%
glucose and/or 0.4% mannose was used. Strains containing the
pMMB67EH vector were grown in the presence of 100 mg/ml Sm
and 50 mg/ml ampicillin (Amp). Expression from the Ptac
promoter was induced by the addition of 1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG). Phage susceptibility was deter-
mined by the soft agar overlay method as described previously
[40] and/or by measuring growth of a bacterial isolate in the
presence of ICP1 (to an approximate MOI=1) in LB plus Sm
broth culture using a Bio-Tek microplate reader.
Isolation of spontaneous manA and wbeL phase variants
and whole genome resequencing
A wild type V. cholerae O1 strain (E7946) was used in standard
plaque assays with phage ICP1 as previously described [40].
Following overnight incubation, colonies were routinely observed in
the center of plaques indicating the presence of phage resistant
isolates. Four independent colonies were chosen for further analysis
including phage resistance assays and whole genome sequencing
using an Illumina genome analyzer II (Tufts University Core
facility) as previously described [40]. Assembled genomes were
aligned to the V. cholerae O1 N16961 [47] and E7946 (unpublished
data) reference genomes. Two of the independently isolated phage
resistant strains had a single nucleotide deletion in the poly-A tract
of wbeL (designated wbeL*), while one phage resistant derivative had
a single nucleotide deletion in the second poly-A tract of manA
(designated manA*). The other derivative not chosen for further
study had a nonsynonymous substitution in manB.
Bacterial strain construction
PCRs for sequencing and cloning were carried out using EasyA
polymerase (Agilent). Primer sequences are available upon request.
In-frame unmarked deletions were constructed using splicing by
overlap extension (SOE) PCR [76] and introduced using
pCVD442-lac [77]. Deletion alleles constructed in this study are
missing the entire open reading frame, except for the start and stop
codons (with the exception of the wbeL deletion allele which also
preserved a single codon immediately upstream of the stop codon).
Expression plasmids were constructed by cloning the desired open
reading frame(s) (including the predicted ribosome binding site)
into the multiple cloning site of pMMB67EH. Expression vectors
were transferred into V. cholerae by conjugation with E. coli
SM10lpir and selection of Sm
R Amp
R colonies. Strains utilized in
this study are shown in Table 3.
LPS analysis
Slide agglutination tests were performed using V. cholerae O1
Ogawa polyclonal rabbit antiserum (Difco). LPS was extracted
from overnight cultures unless otherwise indicated, as described
previously [72]. Briefly, cultures were centrifuged and washed
twice in TM buffer (50 mM Tris [pH 7.5], 10 mM MgCl2)
supplemented with 1 mM DL-Dithiothreitol before being lysed by
bead-beating (BioSpec Products, Inc.) with 0.1 mm zirconia beads
for a total of three minutes with intermittent incubations on ice.
Whole cell lysates were treated with proteinase-K (Sigma) at 37uC
for 24–48 h as required. Phenol extraction was performed using
phase-lock gel light tubes (Eppendorf). Extracts were centrifuged at
75,0006g for 60 min, the pellet was washed with TM buffer and
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NuPage Bis-Tris gel (Invitrogen) and visualized by silver-staining
(SilverQuest, Invitrogen). The concentration of V. cholerae LPS was
determined by comparison to a standard curve of E. coli O26:B6
LPS (Sigma) using a Fujifilm FLA-900 scanner as previously
described [72]. The ability of purified LPS to neutralize plaque
formation was determined as previously described [40].
Infant mouse colonization assays
In vivo competition experiments were done using 4–5 day old
CD-1 mice. The dams and their litters were housed with food and
water ad libitum and monitored in accordance with the rules of the
Department of Laboratory Animal Medicine at Tufts Medical
Center. The inoculum was prepared as a 1:1 mixture of the strain
of interest (lacZ+) and the appropriate control strain (DlacZ). Mice
were infected intragastrically with approximately ,10
5 CFU and
sacrificed 24 hours post-infection. Small intestines were homoge-
nized in 1 ml LB+16% glycerol, diluted in LB broth, and plated
on LB agar plates containing 100 mg/ml Sm and 40 mg/ml 5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal). The
competitive index was calculated as the ratio of the mutant
compared to the control strain normalized to the input ratio. In
vitro controls were included in each of these experiments in which
the same inoculum was diluted 1:100 into at least five independent
LB cultures and the output ratios of mutant to the control strain
were determined on Sm X-gal agar plates as above.
Polymyxin B killing assays
Polymyxin B killing assays were done as previously described
with minor modifications [57]. Briefly, overnight cultures were
subcultured 1:100 into LB and grown at 37uC to the desired OD
(OD600=0.15 and OD600=0.5). 5 ml polymyxin B (Invitrogen) at
500 mg/ml was added to 45 ml of the above culture in a well of a
96-well polypropylene microtiter plate to obtain a final test
concentration of 50 mg/ml polymyxin B. After three hours of
incubation at 37uC with shaking, serial dilutions of each culture
were plated on LB Sm plates. The percent survival was calculated
as (CFU(polymyxin treatment)/CFU(untreated))6100. The average per-
cent survival was determined from two biological replicates, each
having been done in technical duplicate.
Evaluation of phage resistance during growth on chitin
Overnight cultures of wild type V. cholerae E7946 were serially
diluted in filter sterilized pond water to approximately 10
5 CFU/
ml. 10 ml of diluted culture (10
3 CFU) was used to inoculate 1 ml
chitin solution (1% chitin from crab shells [Sigma] in filter
sterilized pond water). To assess the impact of phage on the
appearance of phase variants under these conditions, approxi-
mately 10 PFU of ICP1 was immediately added following
inoculation of bacteria (MOI=0.01). The mixture was allowed
to incubate for 24 hours at 30uC statically at which time the
mixture was vortexed and plated for CFU. ICP1 was enumerated
by adding chloroform to a 100 ml aliquot of the above solution,
diluted and plated for PFU with E7946 using the soft agar overlay
method as described above.
Evaluation of the presence of phase variants in cholera
stool samples
Three cholera stool samples collected at the ICDDR,B in 2001
and stored in the presence of glycerol were assayed for the
Table 3. Strains used in this study.
V. cholerae strains Relevant genotype/description Reference or Source
WT (E7946) Spontaneous SmR derivative of E7946, El Tor Ogawa [79]
wbeL* Spontaneous phage resistant isolate, single nucleotide deletion in poly-A tract
(A8RA7)i nwbeL (VC0249)
This study
DwbeL In-frame deletion of wbeL This study
wbeL*( p wbeL) wbeL* (pMMB67EH::wbeL) This study
DwbeL (pwbeL) DwbeL (pMMB67EH::wbeL) This study
DwbeL (pwbeL*) DwbeL (pMMB67EH::wbeL*) This study
wbeL* (42 AA) wbeL* with a deletion in the remainder of the coding sequence downstream of the
premature stop codon
This study
wbeL* PL wbeL* with nucleotide substitutions within the A7 tract (A7 to TAAGAAA) This study
wbeL* rev Reversion of wbeL* to wild type wbeL This study
manA* Spontaneous phage resistant isolate, single nucleotide deletion in second poly-A tract
(A9RA8))i nmanA (VC0269)
This study
DmanA In-frame deletion of manA (VC0269) This study
DmanA-2 In-frame deletion of manA-2 (VC1827) This study
manA* DmanA-2 In-frame deletion of manA-2 (VC1827) in manA* background This study
DmanA DmanA-2 In-frame deletion of manA-2 (VC1827) in DmanA background This study
manA* rev Reversion of manA* to wild type manA This study
manA*( p manA) manA* (pMMB67EH::manA) This study
DlacZ In-frame deletion of lacZ [80]
waaL waaL::pGp, V. cholerae O1 SV194 background, O1 antigen minus [42]
Bacteriophage
ICP1 O1-specific phage of V. cholerae O1 [40].
doi:10.1371/journal.ppat.1002917.t003
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each sample were found to be O1 Inaba that were sensitive to
ICP1. wbeL* and manA* mutants of this clinical O1 Inaba isolate
were recovered after plating with ICP1 and used to assess the
applicability of replica plating on polymyxin B as a tool to identify
heterogeneity within a stool sample. Both the wbeL* and manA*
isolates in this background failed to grow on LB agar plates
containing 800 mg/ml polymyxin B, while the parental strain
maintained its ability to grow. Each stool sample was plated on LB
agar containing 100 mg/ml Sm and incubated overnight at 37uC.
Plates were then replica plated onto polymyxin B plates and
incubated overnight at 37uC to identify polymyxin B sensitive
isolates in the stool sample. Approximately 5000 colonies were
analyzed per stool sample.
Ethics statement
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University School of Medicine’s Institutional Animal Care and
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with trained husbandry, technical, and veterinary personnel.
Supporting Information
Figure S1 Chemical structure of the V. cholerae O1
antigen, serotypes Ogawa (R=CH3) and Inaba (R=H).
The O1 antigen is composed of 12–18 repeating units (n) of a(1,2)-
linked D-perosamine residues, the amino groups of which are
acylated with tetronate.
(TIF)
Figure S2 The coding sequence of wild type wbeL. The
A8 tract which is mutated to A7 in wbeL* is indicated below the
arrow. The premature stop codon resulting from the frameshift
mutation is indicated in red. The putative ATP-binding domain
[14] is highlighted in gray.
(TIF)
Figure S3 The coding sequence of wild type manA. The
A9 tracts subject to slipped-strand mispairing are indicated below
the arrows. The premature stop codons resulting from the
respective frameshift mutations are indicated in red. The
conserved PMI motif [20] is highlighted in gray. In addition,
amino acids predicted to be involved in zinc ligand binding [78]
are indicated with an asterisk (GLN
104, HIS
106, GLU
141, HIS
264).
(TIF)
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